es-lhfshd-diagnostic-strategy

name

es-lhfshd-diagnostic-strategy

description

This skill determines the appropriate diagnostic strategy for luteinizing hormone/follicle-stimulating hormone deficiency (LH/FSHD) in childhood cancer survivors, recommending the use of the same diagnostic methods (e.g., GnRH stimulation test) as in the noncancer population. It is triggered by clinician questions such as "How should I diagnose LH/FSHD in this survivor?" or "What tests are appropriate for gonadotropin deficiency evaluation?"

Select LH/FSHD diagnostic approach

STEP 1 — Gather Information

Collect history of cranial/spinal radiation dose to the hypothalamic–pituitary axis (≥30 Gy), tumors or surgery affecting the HP region, presence of other anterior pituitary hormone deficits, pubertal staging (Tanner), baseline serum LH, FSH, and sex steroids (testosterone in males, estradiol in females) drawn before 10:00 AM, and assess for delayed or absent pubertal development. If HP axis radiation ≥30 Gy or HP tumors/surgery are present, proceed to evaluate for LH/FSHD; otherwise, consider alternative etiologies and manage accordingly.

STEP 2 — Rule In / Rule Out

First binary fork: Are baseline LH and FSH low or inappropriately normal for low sex steroids? If yes, move to stimulation testing to confirm central deficiency; if no, consider functional suppression or primary gonadal disease and manage accordingly.

STEP 3 — Classify or Stratify

Perform a GnRH stimulation test; classify as LH/FSHD when the peak LH response is <5–8 IU/L and peak FSH <5 IU/L (using assay‑specific cut‑offs). If the test shows a blunted response, diagnose LH/FSHD; if the response is adequate, reconsider the diagnosis and look for other causes.

STEP 4 — Decide

If LH/FSHD is confirmed, initiate sex‑steroid replacement therapy guided by pubertal staging and bone age, using the same regimens as in the noncancer population, monitor LH/FSH and sex steroids every 6–12 months, and adjust dose to achieve pubertal progression; if testing is nondiagnostic, repeat evaluation in 6–12 months or consider a GnRH agonist test. Proceed with treatment or repeat testing as indicated.

Clinical Guardrails / Mimics / Pitfalls

Do not rely solely on basal LH/FSH levels, as they may be normal in early or mild central deficiency; avoid misattributing low LH/FSH to primary gonadal injury without checking for elevated LH/FSH; do not use testicular volume as the sole marker of pubertal progression in males with gonadotoxic exposure; avoid diagnosing LH/FSHD in obese males without correcting for sex‑steroid‑related suppression of gonadotropins; rule out hyperprolactinemia and chronic illness as mimics.

Concrete Clinical Example

A 14‑year‑old male survivor of a suprasellar glioma treated with 36 Gy cranial radiation presents with absent pubertal development (Tanner stage 1), serum testosterone 80 ng/dL (low), LH 1.2 IU/L, FSH 1.5 IU/L (low/normal). A GnRH stimulation test yields peak LH 4.0 IU/L and peak FSH 3.0 IU/L (blunted). LH/FSHD is diagnosed, and testosterone replacement is initiated at a low dose with upward titration every 6 months to mimic pubertal tempo.

Source: Hypothalamic Pituitary and Growth Disorders in Survivors of Childhood Cancer: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2018, DOI:10.1210/jc.2018-01175